Lisata Therapeutics
LSTA
33 hedge funds and large institutions have $6.13M invested in Lisata Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.
460% more call options, than puts
Call options by funds: $280K | Put options by funds: $50K
0% less ownership
Funds ownership: 0.97% → 0.97% (-0%)
3% less funds holding
Funds holding: 34 → 33 (-1)
16% less capital invested
Capital invested by funds: $7.33M → $6.13M (-$1.2M)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$583K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$21.5K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$14.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$13.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$143K |
| 2 |
VF
Virtu Financial
New York
|
-$135K |
| 3 |
Two Sigma Advisers
New York
|
-$76.1K |
| 4 |
Renaissance Technologies
New York
|
-$71.2K |
| 5 |
Two Sigma Investments
New York
|
-$50.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$23 | +2 | +1% |
|
|
KFS
27
Kelly Financial Services
Braintree,
Massachusetts
| $7 | – | – | – |
|
|
AFM
28
Anson Funds Management
Dallas,
Texas
| – | -$143K | -11,295 | Closed |
|
|
VF
29
Virtu Financial
New York
| – | -$135K | -10,684 | Closed |
|
|
IFA
30
Index Fund Advisors
Irvine,
California
| – | -$9K | -696 | Closed |
|
|
SWM
31
Spire Wealth Management
Mclean,
Virginia
| – | -$2K | -152 | Closed |
|
32
Bank of America
Charlotte,
North Carolina
| – | -$57 | -5 | -13% |
|
LSTA Hedge Fund Activity: Q1 2022 in Review
33 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2022, worth a combined $6.13M — down 16% from $7.33M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LSTA and 3 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 7 added.
The largest buyer was Sabby Management, adding an estimated $583K. The largest seller was Anson Funds Management, exiting entirely with an estimated $143K sold.
- 33 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2022, down from 34 in Q4 2021.
- Funds reported $6.13M of Lisata Therapeutics stock for Q1 2022, down 16% quarter-over-quarter.
- 3 funds opened new Lisata Therapeutics positions in Q1 2022 and 4 closed out, a net change of -1 holder.
- The largest Lisata Therapeutics buyer in Q1 2022 was Sabby Management, an estimated $583K added.
- The largest Lisata Therapeutics seller in Q1 2022 was Anson Funds Management, an estimated $143K sold.
Based on aggregated 13F filings for Q1 2022.